JP2019529418A - 抗体およびチェックポイント阻害剤の併用療法 - Google Patents

抗体およびチェックポイント阻害剤の併用療法 Download PDF

Info

Publication number
JP2019529418A
JP2019529418A JP2019514748A JP2019514748A JP2019529418A JP 2019529418 A JP2019529418 A JP 2019529418A JP 2019514748 A JP2019514748 A JP 2019514748A JP 2019514748 A JP2019514748 A JP 2019514748A JP 2019529418 A JP2019529418 A JP 2019529418A
Authority
JP
Japan
Prior art keywords
optionally substituted
cancer tumor
tumor
antibody
combination therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019514748A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529418A5 (https=
Inventor
ティナ・クリスティン・ラブラノス
ダニエル・ジョン・イングリス
クリストファー・エル・レイス
Original Assignee
バイオノミックス リミテッド
バイオノミックス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016903724A external-priority patent/AU2016903724A0/en
Application filed by バイオノミックス リミテッド, バイオノミックス リミテッド filed Critical バイオノミックス リミテッド
Publication of JP2019529418A publication Critical patent/JP2019529418A/ja
Publication of JP2019529418A5 publication Critical patent/JP2019529418A5/ja
Priority to JP2021148016A priority Critical patent/JP7470085B2/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019514748A 2016-09-16 2017-09-14 抗体およびチェックポイント阻害剤の併用療法 Pending JP2019529418A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021148016A JP7470085B2 (ja) 2016-09-16 2021-09-10 抗体およびチェックポイント阻害剤の併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016903724 2016-09-16
AU2016903724A AU2016903724A0 (en) 2016-09-16 Antibody and checkpoint inhibitor combination therapy
PCT/AU2017/050998 WO2018049474A1 (en) 2016-09-16 2017-09-14 Antibody and checkpoint inhibitor combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021148016A Division JP7470085B2 (ja) 2016-09-16 2021-09-10 抗体およびチェックポイント阻害剤の併用療法

Publications (2)

Publication Number Publication Date
JP2019529418A true JP2019529418A (ja) 2019-10-17
JP2019529418A5 JP2019529418A5 (https=) 2019-11-28

Family

ID=61618508

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019514748A Pending JP2019529418A (ja) 2016-09-16 2017-09-14 抗体およびチェックポイント阻害剤の併用療法
JP2021148016A Active JP7470085B2 (ja) 2016-09-16 2021-09-10 抗体およびチェックポイント阻害剤の併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021148016A Active JP7470085B2 (ja) 2016-09-16 2021-09-10 抗体およびチェックポイント阻害剤の併用療法

Country Status (9)

Country Link
US (1) US11655304B2 (https=)
EP (1) EP3512548B1 (https=)
JP (2) JP2019529418A (https=)
KR (1) KR20190053909A (https=)
CN (1) CN109789206A (https=)
AU (1) AU2017326751B2 (https=)
CA (1) CA3035262A1 (https=)
IL (1) IL265274B2 (https=)
WO (1) WO2018049474A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944649C (en) * 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
BR112019005378A2 (pt) * 2016-09-19 2019-08-27 The Trustees Of The University Of Pennsylvania molécula de ácido nucleico, composição, e, métodos para prevenir ou tratar uma doença e para induzir uma resposta imune
EP3672990A1 (en) 2017-08-25 2020-07-01 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
JP2021514379A (ja) 2018-02-21 2021-06-10 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体製剤
MA52416A (fr) 2018-03-02 2021-04-21 Five Prime Therapeutics Inc Anticorps b7-h4 et leurs procédés d'utilisation
EA202191556A1 (ru) * 2018-12-03 2021-10-14 Фьюжн Фармасьютикалз Инк. Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек
CN115151309A (zh) * 2019-12-05 2022-10-04 Ose免疫疗法 抗clec-1a抗体及其抗原结合片段
BR112022018238A2 (pt) 2020-03-13 2022-10-25 Univ Texas Método de tratamento de um câncer em um sujeito
EP4168451A2 (en) 2020-06-22 2023-04-26 NGM Biopharmaceuticals, Inc. Lair-1-binding agents and methods of use thereof
CN112540178B (zh) * 2020-08-06 2023-12-19 武汉天德生物科技有限公司 一种检测早期老年痴呆症的免疫组化试剂盒及其使用方法
CN112608386B (zh) * 2020-12-21 2022-09-23 捷和泰（北京）生物科技有限公司 阻断异嗜性人IgM反应性的单克隆抗体及其制备方法
CN112684185B (zh) * 2020-12-25 2024-01-12 苏州旭光科星抗体生物科技有限公司 一种可溶性b7-h4定量检测试剂盒及其应用
WO2022232255A2 (en) * 2021-04-28 2022-11-03 The Trustees Of Columbia University In The City Of New York Antibodies for the treatment and prevention of covid-19 and emerging variants
WO2022247756A1 (zh) * 2021-05-23 2022-12-01 上海邦耀生物科技有限公司 靶向gprc5d的嵌合抗原受体及其用途
CN113980125B (zh) * 2021-10-15 2024-03-26 中国科学院武汉病毒研究所 一种抗sftsv的中和性单克隆抗体及其应用
CN114957457B (zh) * 2022-05-27 2024-09-24 中国科学院武汉病毒研究所 一种抗ev71病毒中和抗体及其制备方法和应用
CN114989294B (zh) * 2022-05-27 2024-11-05 中国科学院武汉病毒研究所 一种抗ev71病毒抗体及其制备方法和应用
CN114796483B (zh) * 2022-06-28 2022-11-08 北京大学 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物
JP2024137479A (ja) * 2023-03-24 2024-10-07 富士フイルム株式会社 免疫チェックポイント阻害薬による治療効果を予測する方法、上記治療効果を予測するためのデータを得るための方法、上記治療効果を予測する方法又は上記データを得るための方法におけるプロハプトグロビン量の測定のための検査キット

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009531281A (ja) * 2006-02-03 2009-09-03 バイオノミックス リミテッド 置換ベンゾフラン、ベンゾチオフェン、ベンゾセレノフェンおよびインドールおよびそれらのチューブリン重合阻害剤としての使用
JP2014533247A (ja) * 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
WO2015153916A1 (en) * 2014-04-04 2015-10-08 Bionomics, Inc. Humanized antibodies that bind lgr5
WO2016070051A2 (en) * 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2016090024A2 (en) * 2014-12-02 2016-06-09 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
IE921342A1 (en) 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
US8039443B2 (en) 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20050250106A1 (en) 2003-04-24 2005-11-10 David Epstein Gene knock-down by intracellular expression of aptamers
US8278290B2 (en) 2005-02-14 2012-10-02 Biononics Limited Tubulin polymerisation inhibitors
US8466163B2 (en) 2006-12-11 2013-06-18 Bionomics Limited Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization
DK2173379T3 (en) * 2007-07-02 2015-12-07 Oncomed Pharm Inc Compositions and methods for treatment and diagnosis of cancer
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US9341728B2 (en) 2013-07-29 2016-05-17 Westerngeco L.L.C. Methods of analyzing seismic data
WO2015042108A1 (en) 2013-09-17 2015-03-26 Genentech, Inc. Methods of using anti-lgr5 antibodies
UA129760C2 (uk) * 2013-12-17 2025-07-30 Дженентек, Інк. Анти-cd3 антитіло та спосіб його застосування
US10521817B2 (en) 2014-04-02 2019-12-31 Nant Holdings Ip, Llc Augmented pre-paid cards, systems and methods
BR112016028838A2 (pt) 2014-06-11 2017-10-24 Genentech Inc anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2017040660A1 (en) * 2015-08-31 2017-03-09 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US20200114017A1 (en) * 2017-06-16 2020-04-16 Bionomics Limited Antibody drug conjugates that bind lgr5

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009531281A (ja) * 2006-02-03 2009-09-03 バイオノミックス リミテッド 置換ベンゾフラン、ベンゾチオフェン、ベンゾセレノフェンおよびインドールおよびそれらのチューブリン重合阻害剤としての使用
JP2014533247A (ja) * 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
WO2015153916A1 (en) * 2014-04-04 2015-10-08 Bionomics, Inc. Humanized antibodies that bind lgr5
WO2016070051A2 (en) * 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2016090024A2 (en) * 2014-12-02 2016-06-09 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NAT. REV. CANCER (2012) VOL.12, NO.4, P.252-264, JPN6020027800, ISSN: 0004656873 *
がん幹細胞（CANCER STEM CELL）マーカー抗体, コスモバイオ株式会社, 2014-12-07, [検索日2020-07-22], イ, JPN6020027798, ISSN: 0004656875 *
日本臨床免疫学学会誌 (2012) VOL.35, NO.5, P.412-423, JPN6020027797, ISSN: 0004656876 *

Also Published As

Publication number Publication date
EP3512548A4 (en) 2020-04-29
NZ750974A (en) 2024-01-26
IL265274A (en) 2019-05-30
IL265274B2 (en) 2023-11-01
EP3512548B1 (en) 2023-03-22
EP3512548A1 (en) 2019-07-24
KR20190053909A (ko) 2019-05-20
JP2022003046A (ja) 2022-01-11
US11655304B2 (en) 2023-05-23
WO2018049474A1 (en) 2018-03-22
CN109789206A (zh) 2019-05-21
AU2017326751B2 (en) 2024-10-10
IL265274B1 (en) 2023-07-01
AU2017326751A1 (en) 2019-03-14
US20190263925A1 (en) 2019-08-29
JP7470085B2 (ja) 2024-04-17
CA3035262A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
JP7470085B2 (ja) 抗体およびチェックポイント阻害剤の併用療法
EP3419999B1 (en) Antibodies having specificity for btla and uses thereof
JP2018521008A (ja) 腫瘍形成を処置するための治療用組成物および治療方法
US20230256054A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
US20190263911A1 (en) Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use
JP2023554422A (ja) がんの治療のための多重特異性抗体
US20230323470A1 (en) Methods of treating cancer by administering a pd-1 inhibitor
KR20220151161A (ko) Igsf8의 표적화에 의해 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
RU2842292C1 (ru) Способы лечения рака посредством введения ингибитора pd-1
HK40008284A (en) Antibody and checkpoint inhibitor combination therapy
HK40008284B (en) Antibody and checkpoint inhibitor combination therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201223

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210910

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210910

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210928

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211119

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211124

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20211210

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20211214

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240202